Vertex Pharmaceuticals (WBO:VRTX) Beneish M-Score: -2.37 (As of Jun. 24, 2026)


WBO:VRTX Vertex Pharmaceuticals Inc WBO:VRTX
90 GF Score
Price €410.10
GF Value €439.78
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Beneish M-Score?

Vertex Pharmaceuticals WBO:VRTX +2.51% 90 Beneish M-Score is -2.37 as of Jun. 24, 2026. GuruFocus rates WBO:VRTX with a GF Score™ of 90/100 and a GF Value™ of €439.78 (Fairly Valued). The stock has 4 warning signs investors should review. Among 831 Biotechnology companies, Vertex Pharmaceuticals ranks worse than 50.18% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.37 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Vertex Pharmaceuticals's Beneish M-Score or its related term are showing as below:

WBO:VRTX' s Beneish M-Score Range Over the Past 10 Years
Min: -3.17   Med: -2.33   Max: 1.65
Current: -2.37

During the past 13 years, the highest Beneish M-Score of Vertex Pharmaceuticals was 1.65. The lowest was -3.17. And the median was -2.33.


Vertex Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Beneish M-Score Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.35 -2.37 -2.15 -2.29 -2.12

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.35 -3.17 -3.12 -2.12 -2.37

WBO:VRTX vs REGN, ALNY, RVMD: Beneish M-Score Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Beneish M-Score falls into.


WBO:VRTX
90GF Score
Vertex Pharmaceuticals Inc WBO:VRTX
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Vertex Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0143+0.528 * 0.9975+0.404 * 0.9672+0.892 * 1.0195+0.115 * 1.1601
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1078+4.679 * 0.002347-0.327 * 0.9331
=-2.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €1,727 Mil.
Revenue was 2583.668 + 2724.26 + 2621.093 + 2570.395 = €10,499 Mil.
Gross Profit was 2243.896 + 2326.296 + 2267.683 + 2217.092 = €9,055 Mil.
Total Current Assets was €10,147 Mil.
Total Assets was €22,909 Mil.
Property, Plant and Equipment(Net PPE) was €2,849 Mil.
Depreciation, Depletion and Amortization(DDA) was €187 Mil.
Selling, General, & Admin. Expense(SGA) was €1,590 Mil.
Total Current Liabilities was €3,357 Mil.
Long-Term Debt & Capital Lease Obligation was €1,718 Mil.
Net Income was 892.161 + 1017.199 + 922.631 + 895.524 = €3,728 Mil.
Non Operating Income was -0.605 + 70.113 + -53.165 + 8.757 = €25 Mil.
Cash Flow from Operations was 1235.306 + 425.292 + 1057.673 + 930.378 = €3,649 Mil.
Total Receivables was €1,670 Mil.
Revenue was 2562.435 + 2780.96 + 2497.482 + 2457.762 = €10,299 Mil.
Gross Profit was 2226.66 + 2376.613 + 2143.749 + 2112.267 = €8,859 Mil.
Total Current Assets was €9,258 Mil.
Total Assets was €21,164 Mil.
Property, Plant and Equipment(Net PPE) was €2,437 Mil.
Depreciation, Depletion and Amortization(DDA) was €187 Mil.
Selling, General, & Admin. Expense(SGA) was €1,408 Mil.
Total Current Liabilities was €3,499 Mil.
Long-Term Debt & Capital Lease Obligation was €1,525 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1726.626 / 10499.416) / (1669.717 / 10298.639)
=0.16445 / 0.16213
=1.0143

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(8859.289 / 10298.639) / (9054.967 / 10499.416)
=0.860239 / 0.862426
=0.9975

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (10146.709 + 2848.877) / 22909.006) / (1 - (9258.14 + 2436.82) / 21164.462)
=0.43273 / 0.447425
=0.9672

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=10499.416 / 10298.639
=1.0195

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(187.277 / (187.277 + 2436.82)) / (186.753 / (186.753 + 2848.877))
=0.071368 / 0.06152
=1.1601

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1590.301 / 10499.416) / (1408.044 / 10298.639)
=0.151466 / 0.136721
=1.1078

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1718.322 + 3356.719) / 22909.006) / ((1525.417 + 3499.46) / 21164.462)
=0.22153 / 0.23742
=0.9331

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(3727.515 - 25.1 - 3648.649) / 22909.006
=0.002347

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Vertex Pharmaceuticals has a M-score of -2.43 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.37 mean?
Vertex Pharmaceuticals (WBO:VRTX) has a Beneish M-Score of -2.37 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vertex Pharmaceuticals and its competitors. According to the industry distribution chart, Vertex Pharmaceuticals ranks #417 out of 831 companies in the Biotechnology industry, placing it in the top 50.2%.
Is Vertex Pharmaceuticals' Beneish M-Score too high?
Vertex Pharmaceuticals' current Beneish M-Score is -2.37. Based on the distribution chart, Vertex Pharmaceuticals ranks #417 out of 831 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vertex Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Beneish M-Score compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #417 out of 831 companies for Beneish M-Score. This places Vertex Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Beneish M-Score is -2.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €439.78, compared to a current price of €410.10 — trading 6.7% below its estimated fair value. The current Beneish M-Score is -2.37. Vertex Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current Beneish M-Score is -2.37 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €410.10 is trading 6.7% below its estimated GF Value™ of €439.78. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for WBO:VRTX:

  • Beneish M-Score: -2.37
  • GF Value™: €439.78 vs. price of €410.10 (6.7% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
90GF Score

Get the complete analysis for WBO:VRTX

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€410.10
Price
€439.78
GF Value